BlossomHill Therapeutics (NASDAQ:BLSM) Given New $40.00 Price Target at Leerink Partners

BlossomHill Therapeutics (NASDAQ:BLSM) had its price target upped by stock analysts at Leerink Partners from $36.00 to $40.00 in a research note issued on Monday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Leerink Partners’ target price would indicate a potential upside of 56.86% from the company’s current price.

A number of other equities research analysts have also weighed in on BLSM. Zacks Research upgraded shares of BlossomHill Therapeutics to a “hold” rating in a report on Wednesday, September 2nd. HC Wainwright assumed coverage on shares of BlossomHill Therapeutics in a research note on Tuesday, September 1st. They issued a “buy” rating and a $35.00 target price on the stock. Wall Street Zen raised shares of BlossomHill Therapeutics to a “hold” rating in a research report on Saturday, August 15th. Guggenheim lifted their price target on shares of BlossomHill Therapeutics from $30.00 to $40.00 and gave the company a “buy” rating in a research note on Monday. Finally, JPMorgan Chase & Co. assumed coverage on BlossomHill Therapeutics in a report on Tuesday, September 1st. They issued an “overweight” rating and a $28.00 price target for the company. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $35.00.

BlossomHill Therapeutics Trading Down 0.9%

BLSM stock traded down $0.24 during midday trading on Monday, reaching $25.50. The company’s stock had a trading volume of 127,478 shares, compared to its average volume of 223,410. BlossomHill Therapeutics has a 1 year low of $15.25 and a 1 year high of $27.99.

BlossomHill Therapeutics (NASDAQ:BLSM) last issued its earnings results on Friday, September 18th. The company reported ($8.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($7.91). Analysts forecast that BlossomHill Therapeutics will post -3.86 EPS for the current year.

Insider Activity at BlossomHill Therapeutics

In related news, Director John P. Schmid bought 6,000 shares of the company’s stock in a transaction on Monday, August 10th. The shares were acquired at an average price of $16.00 per share, with a total value of $96,000.00. Following the transaction, the director owned 6,000 shares of the company’s stock, valued at $96,000. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, General Counsel Vincent Liptak purchased 2,500 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was bought at an average price of $15.80 per share, for a total transaction of $39,500.00. Following the completion of the acquisition, the general counsel directly owned 109,212 shares in the company, valued at approximately $1,725,549.60. This trade represents a 2.34% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought a total of 1,573,900 shares of company stock valued at $25,181,900 over the last quarter.

About BlossomHill Therapeutics

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.